The Calliditas share price reaction suggests that the Kidney International publication feedback should result in increased uncertainty. The results are mostly in line with should be expected and this negative reaction could only be justified for investors with inflated market expectation expectations. The current Calliditas valuation suggests that this is a small minority of investors.